Docetaxel

CAS 114977-28-5 25 current records 6 historicalSmall Molecule

Who holds supplier records for Docetaxel? 25 organisations hold a current record for Docetaxel: an active US FDA Type II Drug Master File or a CEP. A further 6 organisations have only historical (inactive) DMF filings. 18 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: China (7), India (7), Canada (2), Taiwan (1) and 4 other countries (4); not recorded for 4.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Docetaxel: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/docetaxel

Reading the evidence

  • 25 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 14 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Docetaxel expires 16 May 2036. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (25)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Docetaxel. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Docetaxel sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (18)

Certificates of Suitability on the EDQM register for Docetaxel, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 32 certificates in total, including withdrawn, expired, suspended and repeat certificates.

HolderCountryCertificateIssuedEU GMP at holder's address
HUBEI HAOSUN PHARMACEUTICAL CO., LTD. EzhouCN
CEP 2021-302 - Rev 01
Docetaxel, Process II
Nov 2026Inspected Aug 2024
Belgium
WUHAN CALMLAND PHARMACEUTICALS CO., LTD. WuhanCN
CEP 2022-011 - Rev 01
Docetaxel
Jan 2026Inspected Apr 2026
Croatia
HETERO LABS LIMITED HyderabadIN
CEP 2022-149 - Rev 02
Docetaxel trihydrate
Oct 2025—
SHANDONG ANXIN PHARMACEUTICAL CO., LTD JinanCN
CEP 2025-133 - Rev 00
Docetaxel trihydrate, Shandong Anxin site
Sept 2025Inspected Sept 2023
Austria, outside 3-year window
FUJIAN SOUTH PHARMACEUTICAL CO., LTD. SanmingCN
CEP 2016-204 - Rev 05
Docetaxel
Jul 2025—
INTAS PHARMACEUTICALS LIMITED AhmedabadIN
CEP 2020-155 - Rev 02
Docetaxel, Process-IIb
Jul 2025—
CHONGQING SINTAHO PHARMACEUTICAL CO., LTD. MaliuzuiCN
CEP 2022-295 - Rev 01
Docetaxel
May 2025—
LAURUS LABS LIMITED HyderabadIN
CEP 2012-287 - Rev 02
Docetaxel, Process-2
Feb 2025—
FRESENIUS KABI ONCOLOGY LIMITED KalyaniIN
CEP 2011-189 - Rev 05
Docetaxel trihydrate
Jan 2025—
QILU PHARMACEUTICAL CO., LTD. JinanCN
CEP 2014-105 - Rev 04
Docetaxel
Nov 2024Inspected Feb 2025
Switzerland
INDENA S.P.A. MilanoIT
CEP 2018-094 - Rev 02
Docetaxel trihydrate
Oct 2024Inspected Jun 2026
Italy
SCINOPHARM TAIWAN LTD. Shan-HuaTW
CEP 2016-339 - Rev 01
Docetaxel, Code SPT1298
Sept 2024—
SANOFI WINTHROP INDUSTRIE GentillyFR
CEP 2009-343 - Rev 04
Docetaxel trihydrate
Mar 2024—
MSN LABORATORIES PRIVATE LIMITED Kardanur VillageIN
R1-CEP 2015-336 - Rev 01
Docetaxel
Aug 2023—
DR. REDDY'S LABORATORIES LIMITED HyderabadIN
R1-CEP 2013-109 - Rev 01
Docetaxel
Jul 2022—
SAMYANG HOLDINGS CORPORATION Gyeonggi-doKR
R1-CEP 2013-185 - Rev 01
Docetaxel
Aug 2021—
PHYTON BIOTECH LLC DeltaCA
R1-CEP 2012-105 - Rev 01
Docetaxel
Oct 2019—
POLYMED THERAPEUTICS, INC. HoustonUS
R1-CEP 2012-029 - Rev 01
Docetaxel
Mar 2019—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

Historical records (6)

Organisations whose Type II DMFs for Docetaxel are no longer active. These show a past filing, not current supply.

Show all 6 historical records
  • China · Inactive DMF 27433 · filed Sept 2013
  • MAC CHEM PRODUCTS INDIA PVT LTD
    Inactive DMF 26580 · filed Oct 2012
  • Sichuan Xieli Pharmaceutical Co Ltd
    China · Inactive DMF 26328 · filed Aug 2012
  • India · Inactive DMF 25143 · filed Sept 2011
  • Inactive DMF 21930 · filed Oct 2008
  • SAI PHYTOCEUTICALS PVT LTD
    Inactive DMF 20722 · filed Jun 2007

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (54 listed products contain Docetaxel). The latest listed patent expires 16 May 2036. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Other forms of this substance

A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:

Overview

Docetaxel is a chemotherapy medication that works by interfering with cell division, used primarily in the treatment of breast, lung, prostate, and other cancers. It is a semi-synthetic analogue of paclitaxel and functions as a microtubule inhibitor.

Chemical identity

IUPAC name
[(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1,9,12-trihydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate;trihydrate
Canonical SMILES
CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O.O.O.O
InChIKey
XCDIRYDKECHIPE-QHEQPUDQSA-N
Synonyms
Taxotere API, docetaxel (as trihydrate), docetaxel hydrate, docetaxel trihydrate, rp 56976, rp-56976, taxotere, xrp6976

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Microtubule Inhibitor
Physiologic effect
Microtubule Inhibition

Therapeutic areas

CancerBreast CancerProstate Cancer

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Docetaxel?

25 organisations hold an active US FDA Type II Drug Master File or a CEP for Docetaxel: SCINOPHARM TAIWAN LTD (Taiwan), INDENA SPA (Italy), Chongqing Sintaho Pharmaceutical Co., Ltd. (China), MSN Laboratories Private Limited (India), Qilu Pharmaceutical Co., Ltd. (China), WUHAN CALMLAND PHARMACEUTICALS CO LTD (China), BIOVECTRA INC (Canada) and CENWAY PHARMACEUTICALS CO LTD, and 17 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Docetaxel Drug Master Files are active?

SCINOPHARM TAIWAN LTD (DMF 20942, 20021), INDENA SPA (DMF 23886, 33209), Chongqing Sintaho Pharmaceutical Co., Ltd. (DMF 37224), MSN Laboratories Private Limited (DMF 27457), Qilu Pharmaceutical Co., Ltd. (DMF 23458, 25576), WUHAN CALMLAND PHARMACEUTICALS CO LTD (DMF 36878), BIOVECTRA INC (DMF 21517) and CENWAY PHARMACEUTICALS CO LTD (DMF 23406) and 5 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Docetaxel records mean?

6 organisations have only inactive Type II DMFs for Docetaxel. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does Docetaxel have a European Certificate of Suitability?

Yes. 18 organisations hold a valid CEP for Docetaxel on the EDQM register, including HUBEI HAOSUN PHARMACEUTICAL CO., LTD. Ezhou (CN), WUHAN CALMLAND PHARMACEUTICALS CO., LTD. Wuhan (CN), HETERO LABS LIMITED Hyderabad (IN), SHANDONG ANXIN PHARMACEUTICAL CO., LTD Jinan (CN), FUJIAN SOUTH PHARMACEUTICAL CO., LTD. Sanming (CN) and INTAS PHARMACEUTICALS LIMITED Ahmedabad (IN) and 12 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

Does the FDA Orange Book list patents for products containing Docetaxel?

Yes. The latest patent listed for an approved US product containing Docetaxel expires 16 May 2036, across 54 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Docetaxel supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Docetaxel?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.